Literature DB >> 15653324

Restraining PI3K: mTOR signalling goes back to the membrane.

Laura S Harrington1, Greg M Findlay, Richard F Lamb.   

Abstract

The lipid kinase phosphoinositide 3-kinase (PI3K) is activated in response to various extracellular signals including peptide growth factors such as insulin and insulin-like growth factors (IGFs). Phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P(3)] generated by PI3K is central to the diverse responses elicited by insulin, including glucose homeostasis, proliferation, survival and cell growth. The actions of lipid phosphatases have been considered to be the main means of attenuating PI3K signalling, whereby the principal 3-phosphatase - phosphatase and tensin homologue deleted on chromosome 10 (PTEN) - dephosphorylates PtdIns(3,4,5)P(3), reversing the action of PI3K. Recently, however, another pathway of regulation of PI3K has been identified in which activation of PI3K itself is prevented. This finding, together with earlier work, strongly suggests that a major form of negative feedback inhibition of PI3K results from activated growth signalling via mammalian target of rapamycin (mTOR) and the p70 S6 kinase (S6K) - a pathway that could have consequences for the development of type 2 diabetes and tuberous sclerosis complex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653324     DOI: 10.1016/j.tibs.2004.11.003

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  151 in total

1.  Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.

Authors:  Kangdong Liu; Chanmi Park; Shengqing Li; Ki Won Lee; Haidan Liu; Long He; Nak Kyun Soung; Jong Seog Ahn; Ann M Bode; Ziming Dong; Bo Yeon Kim; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-04-24       Impact factor: 4.944

2.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

3.  Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence.

Authors:  Marina Kolesnichenko; Lixin Hong; Rong Liao; Peter K Vogt; Peiqing Sun
Journal:  Cell Cycle       Date:  2012-06-15       Impact factor: 4.534

4.  Activating the translational repressor 4E-BP or reducing S6K-GSK3β activity prevents accelerated axon growth induced by hyperactive mTOR in vivo.

Authors:  Xuan Gong; Longbo Zhang; Tianxiang Huang; Tiffany V Lin; Laura Miyares; John Wen; Lawrence Hsieh; Angélique Bordey
Journal:  Hum Mol Genet       Date:  2015-07-28       Impact factor: 6.150

5.  A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Authors:  Hailing Cheng; Pixu Liu; Fan Zhang; Erbo Xu; Lynn Symonds; Carolynn E Ohlson; Roderick T Bronson; Sauveur-Michel Maira; Emmanuelle Di Tomaso; Jane Li; Andrea P Myers; Lewis C Cantley; Gordon B Mills; Jean J Zhao
Journal:  Cancer Res       Date:  2013-12-09       Impact factor: 12.701

6.  Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase.

Authors:  Diana W Shineman; Aleksandra S Dain; Minkyu L Kim; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2009-05-05       Impact factor: 3.162

7.  mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1.

Authors:  Joseph G Moloughney; Peter K Kim; Nicole M Vega-Cotto; Chang-Chih Wu; Sisi Zhang; Matthew Adlam; Thomas Lynch; Po-Chien Chou; Joshua D Rabinowitz; Guy Werlen; Estela Jacinto
Journal:  Mol Cell       Date:  2016-08-25       Impact factor: 17.970

Review 8.  A complex interplay between Akt, TSC2 and the two mTOR complexes.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem Soc Trans       Date:  2009-02       Impact factor: 5.407

Review 9.  Common corruption of the mTOR signaling network in human tumors.

Authors:  S Menon; B D Manning
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

10.  Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

Authors:  Jingxiang Huang; Shulin Wu; Chin-Lee Wu; Brendan D Manning
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.